Phase II study of etoposide and alpha-interferon in patients with advanced measurable colorectal carcinoma
- 16 Downloads
Based on encouragingin vitro andin vivo data, 14 consecutive patients with measurable metastatic previously untreated colorectal carcinoma were treated with a combination of intravenous etoposide and subcutaneous alpha-interferon. Etoposide was given at 60 mg/m2 intravenously on days 1–5 and alpha-interferon at 5 million units/m2 subcutaneously on days 1–5; courses were repeated every 21 days. All 14 patients were evaluable for response and toxicity. None of the patients achieved a complete or partial remission. Toxicity of this combination was moderate. Our data suggest that this combination is ineffective against colorectal carcinoma.
Key wordsetoposide alpha-interferon colorectal carcinoma
Unable to display preview. Download preview PDF.
- 1.Boring CC, Squires TS, Tong T. Cancer Statistics, 1992. Ca 42:19–38, 1992Google Scholar
- 2.Poon MA, O'Connell MJ, Wieand HS, Krook JE, Gerstner JB, Tschetter LK, Levitt R, Kardinal CG, Mailliard JA. Biochemical modulation of fluorouracil with leucovorin: Confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J Clin Oncol 9:1967–1972, 1992Google Scholar
- 3.Von Hoff DD.In vitro data supporting interferon plus cytotoxic agent combinations. 18:58–61, 1991Google Scholar
- 4.Krigel RL, Slywotzky CM, Lonberg M, Green MD, Andes WA, Kempf R, Gupta S, Grace W, Spiegel RJ, Muggia FM, Grossberg H. Treatment of epidemic Kaposi's sarcoma with a combination of interferon-alpha-2b and etoposide. J Biol Resp Modif 7:359–364, 1988Google Scholar
- 5.Ajani JA, Welch SR, Raber MN, Fields WS, Krakoff IH. Comprehensive criteria for therapy-induced toxicity. Cancer Invest 8:141–153, 1990Google Scholar